Title:
CONNEXIN 45 INHIBITION FOR THERAPY
Document Type and Number:
Japanese Patent JP2021176848
Kind Code:
A
Abstract:
To provide compositions for treating, preventing, inhibiting the progression of or reducing the likelihood of occurrence of a myocardial infarction-related complication, a cardiac disorder characterized by abnormal conduction and other cardiac conditions.SOLUTION: The present disclosure relates to compositions comprising one or more inhibitors of Connexin 45 (Cx45). Preferably, the inhibitor of Cx45 is a small molecule, protein or nucleic acid. More preferably, the inhibitor of Cx45 is a nucleic acid molecule comprising the DNA sequence encoding the RNA molecule. The present invention also discloses the use of the inhibitor of Cx45 in producing pharmaceuticals for treating, preventing, inhibiting the progression of or reducing the likelihood of occurrence of a myocardial infarction-related complication in a subject.SELECTED DRAWING: Figure 14
Inventors:
EDDY KIZANA
PETER FAHMY
PETER FAHMY
Application Number:
JP2021104925A
Publication Date:
November 11, 2021
Filing Date:
June 24, 2021
Export Citation:
Assignee:
UNIV SYDNEY
WESTERN SYDNEY LOCAL HEALTH DISTR
WESTERN SYDNEY LOCAL HEALTH DISTR
International Classes:
A61K45/00; A61K31/711; A61K35/76; A61K38/00; A61K48/00; A61P9/00; C12N15/113; C12N15/864
Domestic Patent References:
| JP2008528678A | 2008-07-31 |
Attorney, Agent or Firm:
Hiraki International Patent Office
Previous Patent: JPWO2021176847
Next Patent: Antibodies that bind to the human cannabinoid 1 (CB1) receptor
Next Patent: Antibodies that bind to the human cannabinoid 1 (CB1) receptor